Value Biotech/Pharma - Aclaris Therapeutics, Inc.
about 1 year ago
Stock Pursuit
"ACRS: Small-cap biotech at $2.44/share, $174M mkt cap vs $122M net cash. KINect platform for drug discovery. Growing revenue, multiple drugs in pipeline. Trading close to cash value. Potential upside but risky due to small-cap biotech nature."
Sentiment
bullish
Conviction
Medium
Tier
Trade Call
Related Stocks
Episode Information
Episode:
Value Biotech/Pharma - Aclaris Therapeutics, Inc.
Source:
Stock Pursuit
Published:
November 14, 2024
Idea Type:
Stock Idea